Secondary amyloidosis is one of the most serious
complications in chronic inflammatory
diseases such as
rheumatoid arthritis. The extracellular deposit of aggregates of
amyloid leads to target organ dysfunction. The mainstay
treatment of
secondary amyloidosis is the control of underlying
disease activity. Many
reports have reported that
TNF-alpha inhibitors improve clinical outcomes. Here, we encountered a 34-year-old
patient with
juvenile rheumatoid arthritis who developed
secondary amyloidosis despite
treatment with
TNF-alpha inhibitors. We present this case and include a
review of the
literature.